Literature DB >> 18245463

In vivo switching of human melanoma cells between proliferative and invasive states.

Keith S Hoek1, Ossia M Eichhoff, Natalie C Schlegel, Udo Döbbeling, Nikita Kobert, Leo Schaerer, Silvio Hemmi, Reinhard Dummer.   

Abstract

Metastatic melanoma represents a complex and heterogeneous disease for which there are no therapies to improve patient survival. Recent expression profiling of melanoma cell lines identified two transcription signatures, respectively, corresponding with proliferative and invasive cellular phenotypes. A model derived from these findings predicts that in vivo melanoma cells may switch between these states. Here, DNA microarray-characterized cell lines were subjected to in vitro characterization before s.c. injection into immunocompromised mice. Tumor growth rates were measured and postexcision samples were assessed by immunohistochemistry to identify invasive and proliferative signature cells. In vitro tests showed that proliferative signature melanoma cells are faster growing but less motile than invasive signature cells. In vivo proliferative signature cells initiated tumor growth in 14 +/- 3 days postinjection. By comparison, invasive signature cells required a significantly longer (P < 0.001) period of 59 +/- 11 days. Immunohistochemistry showed that regardless of the seed cell signature, tumors showed evidence for both proliferative and invasive cell types. Furthermore, proliferative signature cell types were detected most frequently in the peripheral margin of growing tumors. These data indicate that melanoma cells undergo transcriptional signature switching in vivo likely regulated by local microenvironmental conditions. Our findings challenge previous models of melanoma progression that evoke one-way changes in gene expression. We present a new model for melanoma progression that accounts for transcription signature plasticity and provides a more rational context for explaining observed melanoma biology.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18245463     DOI: 10.1158/0008-5472.CAN-07-2491

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  289 in total

1.  Nanog and Oct4 overexpression increases motility and transmigration of melanoma cells.

Authors:  Aurelie Borrull; Stephanie Ghislin; Frederique Deshayes; Jessica Lauriol; Catherine Alcaide-Loridan; Sandrine Middendorp
Journal:  J Cancer Res Clin Oncol       Date:  2012-03-11       Impact factor: 4.553

Review 2.  Sox proteins in melanocyte development and melanoma.

Authors:  Melissa L Harris; Laura L Baxter; Stacie K Loftus; William J Pavan
Journal:  Pigment Cell Melanoma Res       Date:  2010-04-22       Impact factor: 4.693

Review 3.  Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNγ pathways.

Authors:  Xue Bai; David E Fisher; Keith T Flaherty
Journal:  Nat Rev Clin Oncol       Date:  2019-09       Impact factor: 66.675

4.  Cell cycle analysis can differentiate thin melanomas from dysplastic nevi and reveals accelerated replication in thick melanomas.

Authors:  Gergo Kiszner; Barnabas Wichmann; Istvan B Nemeth; Erika Varga; Nora Meggyeshazi; Ivett Teleki; Peter Balla; Mate E Maros; Karoly Penksza; Tibor Krenacs
Journal:  Virchows Arch       Date:  2014-03-30       Impact factor: 4.064

Review 5.  Adaptive Immune Resistance: How Cancer Protects from Immune Attack.

Authors:  Antoni Ribas
Journal:  Cancer Discov       Date:  2015-08-13       Impact factor: 39.397

6.  Ras and Rho GTPases on the move: The RasGRF connection.

Authors:  Piero Crespo; Fernando Calvo; Victoria Sanz-Moreno
Journal:  Bioarchitecture       Date:  2011-07-01

Review 7.  Immune surveillance in melanoma: From immune attack to melanoma escape and even counterattack.

Authors:  Fade Mahmoud; Bradley Shields; Issam Makhoul; Nathan Avaritt; Henry K Wong; Laura F Hutchins; Sara Shalin; Alan J Tackett
Journal:  Cancer Biol Ther       Date:  2017-05-17       Impact factor: 4.742

8.  NFATc2 is an intrinsic regulator of melanoma dedifferentiation.

Authors:  V Perotti; P Baldassari; A Molla; C Vegetti; I Bersani; A Maurichi; M Santinami; A Anichini; R Mortarini
Journal:  Oncogene       Date:  2015-09-21       Impact factor: 9.867

9.  Lineage Plasticity in Cancer Progression and Treatment.

Authors:  Clémentine Le Magnen; Michael M Shen; Cory Abate-Shen
Journal:  Annu Rev Cancer Biol       Date:  2017-12-01

10.  Inhibiting the MNK1/2-eIF4E axis impairs melanoma phenotype switching and potentiates antitumor immune responses.

Authors:  Fan Huang; Christophe Gonçalves; Margarita Bartish; Joelle Rémy-Sarrazin; Mark E Issa; Brendan Cordeiro; Qianyu Guo; Audrey Emond; Mikhael Attias; William Yang; Dany Plourde; Jie Su; Marina Godoy Gimeno; Yao Zhan; Alba Galán; Tomasz Rzymski; Milena Mazan; Magdalena Masiejczyk; Jacek Faber; Elie Khoury; Alexandre Benoit; Natascha Gagnon; David Dankort; Fabrice Journe; Ghanem E Ghanem; Connie M Krawczyk; H Uri Saragovi; Ciriaco A Piccirillo; Nahum Sonenberg; Ivan Topisirovic; Christopher E Rudd; Wilson H Miller; Sonia V Del Rincón
Journal:  J Clin Invest       Date:  2021-04-15       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.